Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3

Cancer Science

Volumn 104, Issue 8, 2013, Pages 1107-1111

  Takahashi, Kayoko ^a,b   Mizukami, Hiroaki ^a,c   Saga, Yasushi ^b   Takei, Yuji ^b   Urabe, Masashi ^a   Kume, Akihiro ^a   Machida, Shizuo ^b   Fujiwara, Hiroyuki ^b   Suzuki, Mitsuaki ^b   Ozawa, Keiya ^a,c  

^a Center for Molecular Medicine   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c International University of Health and Welfare   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PARVOVIRUS VECTOR; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SKELETAL MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84881104533     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12184     Document Type: Article

References (28)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.
3. Wolfson AH, Sightler SE, Markoe AM et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 1992; 45: 142-6.
4. Lurain J. Uterine cancer. In: Berec J, ed. Novak's Gynecology, 12th edn. Baltimore: Williams & Wilkins, 1996; 1057-77.
5. Makinen T, Veikkola T, Mustjoki S et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001; 20: 4762-73.
6. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
7. Makinen T, Jussila L, Veikkola T et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
8. Takahashi K, Saga Y, Mizukami H et al. Development of a mouse model for lymph node metastasis with endometrial cancer. Cancer Sci 2011; 102: 2272-7.
9. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15: 858-63.
10. Takei Y, Mizukami H, Saga Y et al. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 2007; 120: 278-84.
11. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972; 114: 1012-9.
12. Tanabe H, Takada Y, Minegishi D, Kurematsu M, Masui T, Mizusawa H. Cell line individualization by STR multiplex system in the cell bank found cross contamination between ECV304 and EJ-1/T24. Tiss Cult Res Commun 1999; 18: 329-38.
13. Takei Y, Saga Y, Mizukami H et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther 2008; 7: 704-11.
14. Matsushita T, Elliger S, Elliger C et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-45.
15. Mochizuki S, Mizukami H, Kume A et al. Adeno-associated virus (AAV) vector-mediated liver- and muscle-directed transgene expression using various kinds of promoters and serotypes. Gene Ther Mol Biol 2004; 8: 9-18.
16. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
17. Ogura T, Mizukami H, Mimuro J et al. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med 2006; 8: 990-7.
18. Ishiwata A, Mimuro J, Mizukami H et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med 2009; 11: 1020-9.
19. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-40.
20. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1991; 78: 63-9.
21. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther 2012; 20: 1298-304.
22. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release 2012; 161: 377-88.
23. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-23.
24. Mizukami H, Mimuro J, Ogura T et al. Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther 2006; 17: 921-8.
25. Flotte TR, Trapnell BC, Humphries M et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011; 22: 1239-47.
26. Nathwani AC, Tuddenham EG, Rangarajan S et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65.
27. Sopo M, Anttila M, Sallinen H et al. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. Int J Cancer 2012; 131: 2394-401.
28. Otsuka I, Ono I, Akamatsu H, Sunamori M, Aso T. Pulmonary metastasis from endometrial carcinoma. Int J Gynecol Cancer 2002; 12: 208-13.